Your browser doesn't support javascript.
loading
Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland.
Benzaquen, Michael; Borradori, Luca; Berbis, Philippe; Cazzaniga, Simone; Valero, René; Richard, Marie-Aleth; Feldmeyer, Laurence.
Afiliación
  • Benzaquen M; Department of Dermatology, Hôpital Nord, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille University, Marseille, France. Electronic address: michael.benzaquen@ap-hm.fr.
  • Borradori L; Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Berbis P; Department of Dermatology, Hôpital Nord, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille University, Marseille, France.
  • Cazzaniga S; Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; Centro Studi GISED, Bergamo, Italy.
  • Valero R; Department of Nutrition, Metabolic Diseases, Endocrinology, Hôpital de la Conception, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille University, INSERM 1062, INRA 1260, NORT, Marseille, France.
  • Richard MA; Department of Dermatology, Hôpital La Timone, Assistance Publique-Hôpitaux de Marseille, UMR 911, INSERM CRO2, Centre de recherche en oncologie biologique et oncopharmacologie, Aix-Marseille University, member of the French Bullous Group from the French Society of Dermatology, Marseille, France.
  • Feldmeyer L; Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
J Am Acad Dermatol ; 78(6): 1090-1096, 2018 Jun.
Article en En | MEDLINE | ID: mdl-29274348
BACKGROUND: Case reports have suggested an association between dipeptidyl peptidase-4 inhibitors (DPP4is) and development of bullous pemphigoid (BP). OBJECTIVE: To evaluate the association between DPP4i treatment and development of BP. METHODS: We conducted a retrospective 1:2 case-control study, comparing case patients with diabetes and BP with age- and sex-matched control patients with diabetes issued from Swiss (Bern) and French (Marseille) dermatologic departments from January 1, 2014, to July 31, 2016. RESULTS: We collected 61 case patients with diabetes and BP and 122 controls. DPP4is were associated with an increased risk for development of BP (adjusted odds ratio, 2.64; 95% confidence interval, 1.19-5.85; P = .02), with vildagliptin showing the highest adjusted odds ratio (3.57 [95% confidence interval, 1.07-11.84; P = .04]). Stratified analysis showed a stronger association in males and patients age 80 years or older. DPP4i withdrawal and the initiation of first-line treatments led to clinical remission in 95% of cases. LIMITATIONS: This was a retrospective study in tertiary referral hospitals. We focused the analysis on DPP4i intake, without analyzing the potential isolated effect of metformin. CONCLUSIONS: DPP4is, especially vildagliptin, are associated with an increased risk for development of BP. Their use needs to be carefully evaluated, particularly in high-risk patients, such as males and those age 80 years or older.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Penfigoide Ampolloso / Diabetes Mellitus Tipo 2 / Inhibidores de la Dipeptidil-Peptidasa IV Tipo de estudio: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: J Am Acad Dermatol Año: 2018 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Penfigoide Ampolloso / Diabetes Mellitus Tipo 2 / Inhibidores de la Dipeptidil-Peptidasa IV Tipo de estudio: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: J Am Acad Dermatol Año: 2018 Tipo del documento: Article Pais de publicación: Estados Unidos